Figure 6.

OTSSP167 suppresses tumor growth in vivo and increases the survival of animals bearing intracranial GBM. (A) Representative tumors isolated from the control and OTSSP167-treated groups of subcutaneous tumor model. (B) The mean tumor volumes were assessed at the indicated numbers of days after tumor implantation. (C) Mice bearing U87 xenograft tumor were treated with OTSSP167 (5 μL of 1 μM (dose 1) or 2 μM (dose 2) OTSSP167 in 1% DMSO in PBS per mouse) or vehicle control by intratumoral injection once a week for 4 weeks. Representative images of H&E staining of whole brain sections from control group and OTSSP167 treatment group. (D) Kaplan-Meier survival curves of mice implanted with U87 cells (n=10, **P < 0.01, ***P < 0.001). In vivo animal studies to investigate the effect of OTSSP167 administration on the growth of GSC-driven tumor. Tumor size (E) and survival time (F) were analyzed by using the above same treatment. The survival time of tumor-bearing mice was counted by the end of the 55th day after tumor implantation. (G) Representative IHC staining images of p-AKT(Ser473) and Ki67 expression in U87 xenograft tumor of control and OTSSP167 treatment groups. Sections were counterstained with hematoxylin.